• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vaxcyte, Inc. - Common Stock (NQ:PCVX)

61.09 +0.48 (+0.78%)
Delayed Quote Updated: 2:32 PM EST, Nov 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 830,094
Open 61.38
Bid (Size) 61.05 (400)
Ask (Size) 61.14 (200)
Prev. Close 60.62
Today's Range 60.32 - 61.89
52wk Range 39.87 - 90.75
Shares Outstanding 93,706,790
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Vaxcyte Announces Closing of $1.15 Billion Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes, Including Full Exercise of Underwriters’ Options to Purchase Additional Shares and Convertible Senior Notes
October 09, 2026
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
Vaxcyte Announces Pricing of Concurrent Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes
October 06, 2026
From Vaxcyte, Inc.
Via GlobeNewswire

Performance

52-Week Range 32.7% below 52-week high
61.09
39.8752W Low 90.7552W High
1 Week 4.4% below 1-week high
59.431W Low 63.941W High

Vaxcyte, Inc. - Common Stock (PCVX) traded between $39.87 and $90.75 over the past 52 weeks and last traded at $61.09, 32.7% below its 52-week high. Over the past week it ranged between $59.43 and $63.94.

Past 12 Months
+0.7%
-17.2%
+14.1%
+4.5%
+31.5%
+42.6%
1W +$0.42
1M -$12.72
3M +$7.56
6M +$2.60
YTD +$14.63
1Y +$18.27

PCVX was +42.6% over the past year, +4.5% over six months, +31.5% year to date, +0.7% in the last week.

12 Months vs Market
PCVX
+42.6%
DIA
+9.3%
SPY
+10.5%
QQQ
+8.5%
IWM
+14.3%

Over the past 12 months PCVX returned +42.6% versus DIA (Dow) +9.3%, SPY (S&P 500) +10.5%, QQQ (Nasdaq 100) +8.5% and IWM (Russell 2000) +14.3%.

Volume & Liquidity 0.40× 3-mo avg
Today 830,094 3-mo avg 2.1M
1W
2.0M
1M
3.9M
3M
2.1M
6M
1.8M
YTD
1.6M
1Y
1.6M

PCVX most recently traded 830,094 shares against a 3-month average daily volume of 2.1M.

More News

Read More
News headline image
Vaxcyte’s VAX-31 Meets All Primary Endpoints in Pivotal Phase III OPUS-1 Trial ↗
October 05, 2026
Via MarketBeat
News headline image
Vaxcyte Announces Commencement of Proposed Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes
October 05, 2026
From Vaxcyte, Inc.
Via GlobeNewswire
Keep an eye on the top gainers and losers in Monday's session. ↗
October 05, 2026
Via Chartmill
Monday's session: gap up and gap down stocks ↗
October 05, 2026
Via Chartmill
Discover the top movers in Monday's pre-market session. ↗
October 05, 2026
Via Chartmill
News headline image
Vaxcyte Reports Positive Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company’s 31-Valent Pneumococcal Conjugate Vaccine Candidate
October 05, 2026
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
Vaxcyte to Host Webcast and Conference Call to Present Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company’s 31-Valent Pneumococcal Conjugate Vaccine Candidate
October 04, 2026
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
Vaxcyte Has $2.5 Billion in Cash and a $605 Million Half-Year Loss. Here's How to Read Its CFO's Latest Insider Filing ↗
September 08, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
A Vaxcyte Executive Just Cashed Options Struck at $5.35. Here's What Long-Term Investors Should Know ↗
September 08, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Vaxcyte's CEO Parted With Shares for Taxes. Here's What Long-Term Investors Should Know About the Firm ↗
September 08, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Vaxcyte Appoints Chief Medical Officer and Chief Legal Officer; Narrows Guidance for Expected VAX-31 OPUS-1 Topline Data
September 03, 2026
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
Vaxcyte to Participate in Upcoming Investor Conferences
August 27, 2026
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
Vaxcyte Reports Second Quarter 2026 Financial Results and Provides Business Update
August 05, 2026
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
Vaxcyte to Participate in Upcoming Investor Conferences
July 08, 2026
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
Trevi Therapeutics Is Up 100%, Pivotal bioVenture Adds Anyway. Here's Why That Matters. ↗
June 03, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Vaxcyte Doses First Participant in Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy Adults
June 02, 2026
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
This Biotech Is Up 60%. A Top Healthcare Fund Just Bought Another $11 Million ↗
May 24, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Biotech Stock Is Up 355%. One Fund Added a $169 Million Position Last Quarter ↗
May 24, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Dyne Therapeutics Is Up 40%, but One Biotech Fund Just Disclosed Selling $14 Million Worth of Shares ↗
May 19, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
What This Fund’s $14 Million Ocular Therapeutix Exit Could Signal for Investors ↗
May 19, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Biotech Fund Sells $44.5 Million Erasca Stake After Massive 700% Rally ↗
May 18, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update
May 06, 2026
From Vaxcyte, Inc.
Via GlobeNewswire
News headline image
Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference
April 07, 2026
From Vaxcyte, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Vaxcyte, Inc. - Common Stock publicly traded?
Yes, Vaxcyte, Inc. - Common Stock is publicly traded.
What exchange does Vaxcyte, Inc. - Common Stock trade on?
Vaxcyte, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Vaxcyte, Inc. - Common Stock?
The ticker symbol for Vaxcyte, Inc. - Common Stock is PCVX on the Nasdaq Stock Market
What is the current price of Vaxcyte, Inc. - Common Stock?
The current price of Vaxcyte, Inc. - Common Stock is 61.09
When was Vaxcyte, Inc. - Common Stock last traded?
The last trade of Vaxcyte, Inc. - Common Stock was at 11/03/26 02:32 PM ET
What is the market capitalization of Vaxcyte, Inc. - Common Stock?
The market capitalization of Vaxcyte, Inc. - Common Stock is 5.73B
How many shares of Vaxcyte, Inc. - Common Stock are outstanding?
Vaxcyte, Inc. - Common Stock has 6B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap